Clinical development enters the digital age

The headline appears to refer to a ZS analysis arguing that clinical development is finally ready for a digital transformation, driven by interoperable data, artificial intelligence—particularly agentic AI and large language models—and growing willingness within pharmaceutical companies to change established processes.

The proposed transformation spans the full development lifecycle:
smarter trial design, improved site selection and patient enrollment, automated operations, integrated data flows, and faster, more informed decisions.

Recent industry developments support this trend. H1 and Novo Nordisk announced a strategic collaboration to use AI and healthcare data for study design, site selection, enrollment, and broader clinical-development workflows. H1 will also further develop Novo Nordisk’s StudyHub platform.

Other recent reporting highlights AI ‘teammates’ or agents for clinical trials. One analysis estimated that these systems could reduce operational costs by 40–60% through automation, quality monitoring, and streamlined screening, consent, and enrollment.

Digital and decentralized trial models are also expanding, using telehealth, remote monitoring, electronic consent, wearables, and real-world data to reduce participant burden, broaden access, and potentially shorten timelines.

The main obstacles remain data interoperability, privacy, regulatory acceptance, data quality, cybersecurity, and the need to redesign processes—not merely digitize paper-based workflows.